Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2014 · 10-Q
Revenue$5.57M$5.57M−31.4% vs Q3 2013 Net Income-$6.33M-$6.33MN/M vs Q3 2013 EPS Diluted-$0.15-$0.15N/M vs Q3 2013 Gross Profit$1,509,063−32.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$182,616−71.5% Free Cash Flowderived-$4,455,649N/M Margins · derivedGross margin27.1%−0.5 pt vs Q3 2013
Operating margin-107.6%−74.5 pt vs Q3 2013
Net margin-113.7%−85.3 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 14, 2014 · 45 d after period end